Departments of Radiopharmaceutical Cancer Research
- Small molecule and peptide-based radiotracer
- Preclinical Characterization of Radioconjugates
- Therapeutic Alpha-Emitters
- Multi-targeted Radiotheranostics
- Biological evaluation and modulation of targeted, radiometal-based bioconjugates
- Radiotracer and Drug Development
- Theranostic Targets and Experimental Models
- Radiopharmacology and Cancer Imaging
- Tissue Remodeling and Inflammation Imaging
- Radiometals and Functional Labeling Chemistry
- Metabolic and Immune Imaging Biomarkers
- Quantitative parameters for the evaluation of oncological PET
- AI-based delineation of tumors and reference regions in PET
- AI-based enhancement of image quality and quantification in PET
- Quantitative parameters for the evaluation of functional MRI data (fMRI)
- Antibody-based immunotheranostics for tumor therapy and diagnosis
- Adapter CAR-based immunotheranostics for personalized immunotherapy and diagnosis
- Modulation of tumor microenvironment
- Development of immuno- and radiotherapy
- Personalized immunotheranostics for acute myeloid leukemia
- Bionanoelectronics
- 3D Bioreactors
- Droplets microfluidics for clinical diagnostics
- Molecular imaging of the adenosine receptors A2A and A2B
- PET Imaging of the Human Cannabinoid Receptors Type 2 (CB2R) in the Brain
- Brain tumour proliferation imaging - Development of PET radioligands for sigma2 receptors
- Development of PET radioligands for imaging of mutant isocitrate dehydrogenase 1 (mIDH1) in brain tumours
- Development of PSMA ligands for the diagnosis and treatment of prostate cancer
- Production of radioisotopes at the proton accelerator cyclotron TR-Flex by means of (p,X) nuclear reactions.
- Development of new target technology, target preparation processes and processes for the separation and preparation of radionuclides.
- Supply of the Institute for Radiopharmaceutical Cancer Research and external cooperation partners with radionuclides for research and development such as 18F, 11C, 64Cu, 67Cu, 131Ba, 133La, 197(m)Hg, ...
- Providing PET radiopharmaceuticals for daily clinical use (18F-FDG, 18F-FDOPA, 18F-PSMA-1007, 18F-FMISO, 11C-methionine) according to GMP and AMG including quality control.
- GMP-compliant transfer of newly developed radiotracers and manufacturing processes into clinical application.
- Scaling of the processes for the generation of radionuclides and the production of radiopharmaceuticals to industrial scale and knowledge transfer to industrial partners.
- Cooperation with external accelerator facilities to integrate alternative nuclear reactions into the nuclide production process.
×